LRRC19 and pancreatic neoplasm: Manuel H. et al. reported the LRRC19 gene expression > insulin-like growth factor binding protein 2 (IGFBP2) gene expression as a biomarker for pancreatic cancer sensitivity to AZD0530, an orally active small molecule Src inhibitor [66].